Lake Street lowered the firm’s price target on PAVmed to $4 from $22.50 and keeps a Buy rating on the shares, noting that its revised target is 15-for-1 split-adjusted. Record quarterly revenue of $1.0M, up 33% quarter-over-quarter, was “the result of solid traction in the Lucid business,” says the analyst, who also notes that the company filed a going concern given the repayment of some Lucid debt fell within one year. However, the firm expects the maturity will be extended and the recent financing to relieve the going concern, the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAVM:
- PAVmed reports Q4 EPS ($1.33), two estimates ($1.79)
- PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
- PAVM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Lucid Diagnostics announces data from clinical validation study of EsoGuardPAVmed
- PAVmed Inc. Distributes Lucid Stock and Adjusts Warrant Terms